StockNews.com Begins Coverage on Accelerate Diagnostics (NASDAQ:AXDX)

Stock analysts at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDXGet Free Report) in a research note issued to investors on Tuesday. The firm set a “hold” rating on the medical research company’s stock.

Separately, BTIG Research raised Accelerate Diagnostics to a “strong-buy” rating in a research note on Wednesday, December 11th.

Check Out Our Latest Stock Analysis on Accelerate Diagnostics

Accelerate Diagnostics Stock Performance

NASDAQ AXDX opened at $1.31 on Tuesday. The business’s fifty day moving average is $1.30 and its 200 day moving average is $1.54. Accelerate Diagnostics has a fifty-two week low of $0.73 and a fifty-two week high of $2.09. The company has a market capitalization of $32.80 million, a PE ratio of -0.46 and a beta of 0.59.

Insider Activity at Accelerate Diagnostics

In related news, Director John Patience bought 200,000 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were acquired at an average price of $1.57 per share, with a total value of $314,000.00. Following the transaction, the director now owns 653,224 shares of the company’s stock, valued at $1,025,561.68. The trade was a 44.13 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 43.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Accelerate Diagnostics stock. Y Intercept Hong Kong Ltd purchased a new position in Accelerate Diagnostics, Inc. (NASDAQ:AXDXFree Report) during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 19,866 shares of the medical research company’s stock, valued at approximately $34,000. Y Intercept Hong Kong Ltd owned 0.08% of Accelerate Diagnostics at the end of the most recent quarter. Institutional investors own 17.14% of the company’s stock.

Accelerate Diagnostics Company Profile

(Get Free Report)

Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.

Featured Stories

Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.